Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
The list of drug companies forced into several hundred million dollar settlements for making fraudulent product claims continues to lengthen. And the signs are that the US government will continue to ramp up its efforts, using new theories of liability and handing out even stiffer penalties. Mark Ratner investigates.
Only one drug targeting the proteasome protein degradation pathway has been approved, but several second-generation inhibitors are making progress in trials. Jim Kling reports.
Impatient with the slow pace of clinical research, families of individuals suffering from untreatable diseases are taking matters into their own hands—with some success. Virginia Hughes reports.
Researchers are testing a slew of targeted therapeutic strategies in lung cancer. Signs are emerging that these therapies are gaining increasing traction in what has long been one of oncology's minefields. Malorye Allison investigates.
Genetic testing for rare heart conditions might someday expand to more common cardiac ailments. Already there are signs testing is dramatically changing how some conditions are treated and doctors' definition of who a patient is. Stephen Strauss reports.
Surging interest in cancer bioenergetics has brought drug developers into the fray, but the field awaits a clinical success. Ken Garber explores the extent to which the concept is entering the mainstream.
With monogenetic neurodevelopmental disorders similar to autism serving as starting points for several drug discovery programs, smaller biotechs are now joining big pharma in pursuing therapies to tackle this perplexing condition. Sarah Webb reports.
US drug companies are preparing for new draconian provisions for reporting on financial relationships with academia. Will efforts to increase transparency prove burdensome to researchers and the industry? Virginia Hughes investigates.
Dairy farmers are rapidly adopting molecular profiling to accelerate the process of siring cows. But this seismic shift in breeding practices is raising new questions and translating more slowly to the beef industry. Stephen Strauss reports.
Social media represent a new way for drug companies to interact with consumers. But transitioning medical communication and marketing campaigns to the internet poses several thorny legal and regulatory issues. Sarah Webb investigates.
Argentina has blazed a trail as one of the leading genetically modified (GM) crop producers. Can other developing countries import the seeds of its success? Lucas Laursen investigates.
The eye, and particularly the retina, has become a favored testing ground for new biologic drugs. How well novel nucleic acid and cellular therapies work in retinal disease could determine their expansion to other indications. Ken Garber reports.
Although mergers and acquisitions (M&As) failed to hit the heights some analysts had predicted in 2009, a new type of tiered transaction rose to prominence—the structured deal. Randy Osborne reports.
Problems in interpreting diagnostic tests for HER2 may be compromising patient access to effective treatments. As new versions of therapies targeting HER2 work their way through clinical trials, will the situation get even murkier? Malorye Allison investigates.
Cloud computing offers solutions for companies wrestling with large-scale data sets, but security issues will likely continue to restrict its use to precompetitive or nonconfidential data. Clare Sansom reports.
